Entity

Time filter

Source Type


Yang F.-Y.,Central Hospital of Wuhan | Ma G.-T.,Guangxi Medical University
Journal of Invasive Cardiology | Year: 2010

Anomalous origin of left anterior descending (LAD) and left circumflex (LCX) coronary artery from two separate ostia in the right sinus of Valsalva (RSOV) with unusual dominant right coronary artery is an exceedingly rare congenital coronary anomaly. We report a case of a 69-year old woman who was admitted to the hospital because of atypical chest pain. Both multislice computed tomography and coronary angiography revealed this kind of anomaly. Since the benign anomaly and the absence of definite ischemia, the patient doesn't need any specific therapy for this anomaly and is required regular follow-up. Source


Huang L.,Huazhong University of Science and Technology | Liu X.,Huazhong University of Science and Technology | Cheng B.,Central Hospital of Wuhan | Huang K.,Huazhong University of Science and Technology | Huang K.,Wuhan Institute of Biotechnology
Archives of Biochemistry and Biophysics | Year: 2015

The process of protein aggregation from soluble amyloidogenic proteins to insoluble amyloid fibrils plays significant roles in the onset of over 30 human amyloidogenic diseases, such as Prion disease, Alzheimer's disease and type 2 diabetes mellitus. Amyloid deposits are commonly found in patients suffered from amyloidosis; however, such deposits are rarely seen in healthy individuals, which may be largely attributed to the self-regulation in vivo. A vast number of physiological factors have been demonstrated to directly affect the process of amyloid formation in vivo. In this review, physiological factors that influence amyloidosis, including biological factors (chaperones, natural antibodies, enzymes, lipids and saccharides) and physicochemical factors (metal ions, pH environment, crowding and pressure, etc.), together with the mechanisms underlying these proteostasis effects, are summarized. © 2015 Elsevier Inc. Source


Zhu S.,Zhengzhou University | Liu J.-H.,Central Hospital of Wuhan
Pharmacology | Year: 2015

This study was conducted to explore the effect of zerumbone, isolated from Zingiberzerumbet Smith, on apolipoprotein A-I (apoA-I)-mediated cholesterol efflux from THP-1 macrophages. THP-1 macrophages were treated with different concentrations (10-100 μmol/l) of zerumbone and cholesterol efflux was measured. The involvement of ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 and ERK1/2 signaling was checked. Notably, zerumbone caused a concentration-dependent induction of ABCA1 but not ABCG1, coupled with enhanced phosphorylation of ERK1/2. Pre-treatment with PD98059 (a potent ERK1/2 inhibitor) significantly blocked the upregulation of ABCA1 by zerumbone. Small interfering RNA-mediated downregulation of ABCA1 but not ABCG1 significantly impaired the promotion of apoA-I-mediated cholesterol efflux by zerumbone. Taken together, zerumbone has the capacity to facilitate apoA-I-mediated cholesterol efflux from macrophages through the activation of ERK1/2 signaling and upregulation of ABCA1. © 2015 S. Karger AG, Basel. Source


Li N.,Sun Yat Sen University | Ou W.,Sun Yat Sen University | Yang H.,Central Hospital of Wuhan | Liu Q.-W.,Sun Yat Sen University | And 3 more authors.
Cancer | Year: 2014

BACKGROUND The current study was undertaken to investigate the efficacy and safety of erlotinib versus pemetrexed as second-line therapy for patients with advanced epidermal growth factor receptor (EGFR) wild-type and EGFR fluorescence in situ hybridization (FISH)-positive lung adenocarcinoma. METHODS In this open-label, randomized, phase 2 study, patients with EGFR wild-type and EGFR FISH-positive adenocarcinoma who had developed disease progression after 1 prior platinum-based chemotherapy were randomly assigned (1:1) to receive erlotinib or pemetrexed until the time of disease progression or death, unacceptable toxicity, or a request for discontinuation by the patient. The primary endpoint was progression-free survival (PFS). RESULTS A total of 123 patients were enrolled (61 in the erlotinib arm and 62 in the pemetrexed arm). The median PFS was 4.1 months (95% confidence interval [95% CI], 1.6 months-6.6 months) in the erlotinib group versus 3.9 months (95% CI, 2.7 months-5.1 months) in the pemetrexed group. The difference in PFS between the 2 treatment groups was not significant (hazard ratio, 0.92; 95% CI, 0.62-1.37 [P = .683]). The objective response rate appeared to be higher among patients receiving erlotinib compared with those receiving pemetrexed (19.7% vs 8.1%; P = .062). The 3 most commonly recorded adverse events were rash (54.1%), fatigue (19.7%), and diarrhea (16.4%) in the erlotinib group and fatigue (25.8%), nausea (24.2%), and anorexia (14.5%) in the pemetrexed group. CONCLUSIONS There were no significant differences noted with regard to efficacy between erlotinib and pemetrexed in the second-line setting for patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma. Both regimens appear to be effective treatment options for these patients. Cancer 2014;120:1379-1386. © 2014 American Cancer Society. The results of the current randomized phase 2 trial demonstrate that there are no significant differences in efficacy between erlotinib and pemetrexed in the second-line setting for patients with advanced epidermal growth factor receptor wild-type and epidermal growth factor receptor fluorescence in situ hybridization-positive lung adenocarcinoma, and both regimens are effective treatment options in the second-line setting for these patients. © 2014 American Cancer Society. Source


Chen B.,No.1 Peoples Hospital of Jingmen | Huang T.,Huazhong University of Science and Technology | Jiang J.,Central Hospital of Wuhan | Lv L.,Huazhong University of Science and Technology | And 2 more authors.
Molecular and Cellular Biochemistry | Year: 2014

miR-141 belongs to the miR-200 family, and has been found to be associated with numerous human malignancies; however, its role in gastric cancer (GC) has not been examined in detail. Here, we validated that miR-141 was decreased in GC tissues and cell lines. Forced expression of miR-141 significantly repressed GC cell proliferation and colony formation. Furthermore, miR-141 suppressed in vitro migration and invasion of GC cells. Hepatoma-derived growth factor (HDGF) was confirmed to be a direct target of miR-141 in GC cells. The suppressive effects of miR-141 on GC cell proliferation, colony formation, in vitro migration, and invasion were partially mediated by suppressing HDGF expression. Moreover, the expression of HDGF was negatively correlated with miR-141 in GC tissues. Our data suggest that miR-141 might be associated and plays essential role in GC progression. © 2013 Springer Science+Business Media New York. Source

Discover hidden collaborations